Tempest Therapeutics: Storming Ahead with 2024 Financials and Game-Changing Partnerships!

Ladies and gentlemen, buckle up! Tempest Therapeutics, Inc. (Nasdaq: TPST) just dropped their year-end 2024 financial results, and let me tell you, this biotech powerhouse is on FIRE! With a lean team and a laser focus on execution, Tempest is storming ahead in the fight against cancer. Let's dive into the numbers and see what's driving this incredible momentum!

First things first, let's talk about the elephant in the room: cash. Tempest ended 2024 with $30.3 million in cash and cash equivalents, down from $39.2 million at the end of 2023. But don't let that fool you! This decrease is a direct result of Tempest's aggressive investment in research and development, with R&D expenses skyrocketing to $26.8 million, up from $18.2 million in 2023. That's right, folks! Tempest is putting its money where its mouth is, and it's paying off BIG TIME!

Now, let's talk about the star of the show: Amezalpat (TPST-1120). This clinical PPARα antagonist is Tempest's secret weapon in the fight against hepatocellular carcinoma (HCC), and it's already making waves. With both Orphan Drug and Fast Track designations from the FDA, Amezalpat is poised to revolutionize the treatment of HCC. And the best part? Tempest just announced an agreement with Roche to advance Amezalpat into a pivotal Phase 3 trial for first-line HCC treatment. That's right, folks! Tempest is teaming up with one of the biggest players in the game, and it's a game-changer!



But that's not all, folks! Tempest is also making strides with TPST-1495, a clinical dual EP2/4 prostaglandin receptor antagonist. With a "Study May Proceed" letter from the FDA, Tempest is gearing up to advance TPST-1495 into a Phase 2 study for the treatment of Familial Adenomatous Polyposis (FAP) in 2025. And with data expected in 2026, Tempest is positioning itself as a leader in the fight against cancer.

So, what does all this mean for Tempest Therapeutics? It means that this biotech powerhouse is on the verge of a breakthrough, and you don't want to miss out! With a lean team, a laser focus on execution, and game-changing partnerships, Tempest is storming ahead in the fight against cancer. So, do yourself a favor and get in on the action NOW! Tempest Therapeutics is the next big thing in biotech, and you won't want to be left behind!